Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events

American Journal of Medicine

Volumn 123, Issue 4, 2010, Pages

  Salpeter, Shelley R ^a,b   Wall, Andrew J ^a,b   Buckley, Nicholas S ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Asthma; Inhaled corticosteroids; Intubation; Long acting beta agonists; Meta analysis; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; PLACEBO; SALMETEROL; SALMETEROL XINAFOATE;

ARTICLE; ASTHMA; CLINICAL TRIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; INTUBATION; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; FEMALE; HUMANS; INTUBATION, INTRATRACHEAL; MALE; ODDS RATIO;

EID: 77950051793     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2009.07.035     Document Type: Article

References (43)

1. US Food and Drug Administration Office of Surveillance and Epidemiology. Risks and benefits of long-acting beta adrenergic agonists in the treatment of asthma. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf Accessed December 6, 2008
2. Kramer J.M. Balancing the benefits and risks of inhaled long-acting beta-agonists-the influence of values. N Engl J Med 360 (2009) 1592-1595
3. Drazen J.M., and O'Byrne P.M. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 360 (2009) 1671-1672
4. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Long-acting beta-agonists increase severe asthma exacerbations and asthma-related deaths: meta-analysis of randomized controlled trials. Ann Intern Med 144 (2006) 904-912
5. Cates C.J., and Cates M.J. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev (2008) CD006363
6. Cates C.J., Cates M.J., and Lasserson T.J. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 4 (2008) CD006923
7. Sears M.R., Ottosson A., Radner F., and Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 33 (2009) 21-32
8. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis. Statistical briefing package for Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee and Pediatric Advisory Committee on December 10-11, 2008. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b-01-FDA.pdf Accessed December 6, 2008
9. GlaxoSmithKline. Sponsor briefing information. Benefit risk assessment of salmeterol for the treatment of asthma in adults and children. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-04-GSK.pdf Accessed December 6, 2008
10. Novartis. Foradil. FDA Advisory Committee meeting on the safety of long-acting beta2-agonists for the treatment of asthma in adults and children (December 10-11, 2008). Briefing document. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-02-Novartis.pdf Accessed December 6, 2008
11. AstraZeneca. AstraZeneca briefing materials: Review of the benefits and risks of formoterol-containing products. http://www/fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-03-AstraZeneca.pdf Accessed December 6, 2008
12. Jaeschke R., O'Byrne P.M., Mejza F., et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis. Am J Respir Crit Care Med 178 (2008) 1009-1016
13. Jaeschke R., O'Byrne P.M., Nair P., et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and meta-analysis. Pol Arch Med Wewn 118 (2008) 627-635
14. Bateman E., Nelson H., Bousquet J., et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149 (2008) 33-42
15. Rodrigo G.J., Moral V.P., Marcos L.G., and Castro-Rodriguez J.A. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 22 (2009) 9-19
16. US Food and Drug Administration. Summary minutes of the joint Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee, December 10-11, 2008. http://www.fda.gov/ohrms/dockets/AC/08/minutes/2008-4398m1-final.pdf Accessed February 6, 2009
17. Bradburn M.J., Deeks J.J., Berlin J.A., and Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26 (2007) 53-77
18. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
19. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. BMJ 326 (2003) 219
20. U.S Food and Drug Association. Center for Drug Evaluation and Review. Foradil (Formoterol Fumarate inhalation) aerolizer. Part 4. http://www.fda.gov/cder/foi/nda/2001/20831_Foradil_medr_P4.pdf Accessed September 3, 2005
21. U.S Food and Drug Association. Center for Drug Evaluation and Review. Foradil (Formoterol Fumarate inhalation) aerolizer. Part 5. http://www.fda.gov/cder/foi/nda/2001/20831_Foradil_medr_P5.pdf Accessed September 3, 2005
22. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
23. Ind P.W., Dal Negro R., Colman N.C., et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 97 (2003) 555-562
24. Kelsen S.G., Church N.L., Gillman S.A., et al. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma 36 (1999) 703-715
25. Kemp J.P., Cook D.A., Incaudo G.A., et al. Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group. J Allergy Clin Immunol 101 2 Pt 1 (1998) 188-195
26. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 8 Pt 1 (2001) 1392-1397
27. O'Byrne P.M., Bisgaard H., Godard P.P., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171 (2005) 129-136
28. Von Berg A., Papageorgiou Saxoni F., Wille S., et al. Efficacy and tolerability of formoterol Turbuhaler in children. Int J Clin Pract 57 (2003) 852-856
29. U.S Food and Drug Administration. NDA 020831 Formoterol fumarate clinical review. http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4148B1_03_03-FDA-Clinical-Review.pdf Accessed September 3, 2005
30. Patterns of medication use in the United States, 2006. A Report from the Slone Survey. http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurveyWebReport2006.pdf Accessed February 21, 2009
31. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140 (2004) 802-813
32. Lipworth B.J. Long-acting beta(2)-adrenoceptor agonists: a smart choice for asthma?. Trends Pharmacol Sci 28 (2007) 257-262 Epub 2007 Apr 26
33. Sears M.R., Taylor D.R., Print C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336 (1990) 1391-1396
34. Kalra S., Swystun V.A., Bhagat R., and Cockcroft D.W. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 109 (1996) 953-956
35. Spitzer W.O., Suissa S., Ernst P., et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326 (1992) 501-506
36. Kerrebijn K.F., van Essen-Zandviet E.E.M., and Neijens J.J. Effects of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 79 (1987) 653-659
37. Suissa S., and Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 107 (2001) 937-944
38. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 120 5 Suppl (2007) S94-S138
39. Gross N.J. Anticholinergic agents in asthma and COPD. Eur J Pharmacol 533 (2006) 36-39
40. Currie G.P., Lee D.K., and Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma?. Chest 128 (2005) 2954-2962
41. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr Opin Pulm Med 12 (2006) 60-67
42. Salpeter S.R., and Buckley N.S. Author's response: Asthma-related death rate. http://www.annals.org/cgi/eletters/144/12/904#3689 Accessed February 22, 2009
43. Wijesinghe M., Perrin K., Harwood M., et al. The risk of asthma mortality with inhaled long acting beta-agonists. Postgrad Med J 84 (2008) 467-472